Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07564414 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,500
- Enrollment target
NCT07564414: Recruiting Phase 3 study, sponsored by Novo Nordisk A/S.
NCT07564414 is a Phase 3 study that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 2,500 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (224% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07564414, a Phase 3 study, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,500 participants
- Enrollment target
Study Summary
This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive either CagriSema or semaglutide, and which treatment participants receive is decided by chance. CagriSema is a new study medicine being tested, while semaglutide is a medicine that doctors can already prescribe. The study will last for about 83 weeks
Primary Outcome
Measured as percentage (%).
Interventions
- DRUG Semaglutide
- DRUG Cagrisema
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2028-04-19 |
| Phase | Phase 3 |
What NCT07564414 shows while recruiting
NCT07564414 is an interventional study that assigns participants to a tested intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (224% higher).
The record links to 0 conditions, and to 2 interventions - of which Semaglutide is the first listed.
NCT07564414 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07564414 about?
NCT07564414 is a clinical study titled "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight". This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eith...
What is the current status of trial NCT07564414?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,500 participants. The study started on 2026-05-21. Estimated completion is 2028-04-19.
What interventions are being tested in trial NCT07564414?
The interventions under investigation include: Semaglutide (DRUG), Cagrisema (DRUG).
Who is sponsoring clinical trial NCT07564414?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07564414's enrollment target sits among peer trials
2,500 88th of 2000 higher than 1,913 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI